

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

DELAY IN DESPATCH OF CIRCULAR REGARDING NON-EXEMPT CONTINUING CONNECTED TRANSACTION – SERVICES AGREEMENT

We refer to the announcement (the “**Announcement**”) of Alibaba Health Information Technology Limited (the “**Company**”) dated April 1, 2016 in relation to, among other things, the non-exempt continuing connected transactions contemplated under the services agreement (the “**Services Agreement**”) entered into between Alibaba Health Technology (Beijing) Company Limited, a wholly owned subsidiary of the Company, and the Tmall Entities on April 1, 2016. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things: (i) further details of the Services Agreement, (ii) the advice and recommendations of the Independent Board Committee; (iii) the advice and recommendations of the Independent Financial Adviser; and (iv) notice of the SGM, would be despatched to the Shareholders on or before April 25, 2016.

As additional time is required to prepare and finalize the Circular, including but not limited to the letter from the Independent Financial Adviser, the Company expects that the despatch date of the Circular will be delayed to a date on or around May 25, 2016.

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
WANG Lei
Chief Executive Officer and Executive Director

Hong Kong, April 25, 2016

As at the date of this announcement, the Board comprises nine Directors, of which (i) two are executive Directors, namely, Ms. CHEN Xiao Ying and Mr. WANG Lei; (ii) four are non-executive Directors, namely, Mr. WU Yongming, Mr. TSAI Chung, Joseph, Ms. HUANG Aizhu and Mr. KANG Kai; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.